お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:緑内障治療の世界市場:分析と予測
市場調査レポート
商品コード
752346

緑内障治療の世界市場:分析と予測

Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country - 2018 Edition, Forecast to 2023

出版日: | 発行: Azoth Analytics | ページ情報: 英文 239 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
緑内障治療の世界市場:分析と予測
出版日: 2018年11月30日
発行: Azoth Analytics
ページ情報: 英文 239 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の緑内障治療市場について調査分析し、統計と情報 (市場規模・シェア・成長要因) のほか、新興動向、主要促進要因、課題と機会、主要企業について、体系的な情報を提供しています。

第1章 調査手法

第2章 エグゼクティブサマリー

第3章 戦略的提言

第4章 緑内障治療市場の概要

第5章 世界の緑内障治療市場:成長率と予測

  • 金額別 (実績)
  • 金額別 (予測)

第6章 世界の緑内障治療市場:適応別分析

  • 適応別:内訳
  • 開放隅角緑内障
  • 閉塞隅角緑内障
  • 続発性緑内障
  • 先天性緑内障
  • その他

第7章 世界の緑内障治療市場:薬剤分類別分析

  • 薬剤分類別:内訳
  • プロスタグランジン類似体
  • アルファ作動薬
  • 炭酸脱水酵素阻害薬
  • その他

第8章 世界の緑内障治療市場:販路別分析

  • 販路別:内訳
  • 病院薬局
  • 小売薬局
  • その他

第9章 世界の緑内障治療市場:地域別分析

  • 地域別:内訳
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向

第12章 競合情勢

第13章 政策・規制情勢

第14章 ファイブフォース分析

第15章 SWOT分析

第16章 企業プロファイル

  • Teva Pharmaceuticals
  • Ocular Therapeutix
  • Pfizer
  • Bausch Health
  • Novartis
  • Allergan Plc.
  • Aerie Pharmaceuticals
  • Akorn Inc.
図表

List of Figures

  • Figure 1: Global Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 2: Global Glaucoma Treatment Market Size, By Value, Forecast, 2018-2023(USD Million)
  • Figure 3: Global Leading Cause of Blindness
  • Figure 4: Global Prevalence of Glaucoma (2013,2020F, 2040F, Million)
  • Figure 5: Global Diabetes Prevalence (2017 & 2045, Million)
  • Figure 6: Population ages 65 and above, By Select Region, 2013-2017 (% of total)
  • Figure 7: Projected global population aged 60 years & above (In Billions)
  • Figure 8: Projected global population (In Billions)
  • Figure 9: Global Health Expenditure Per Capita, By Select Countries,(2016, USD)
  • Figure 10: Global Health Expenditure Per Capita, (2012-2016, USD Trillion)
  • Figure 11: GDP Per Capita PPP, By Region, 2018 (in Thousand USD)
  • Figure 12: GDP Per Capita PPP, By Select Countries, 2022F (USD)
  • Figure 13: Global Glaucoma Treatment Market Size, By Indication, 2017 (%)
  • Figure 14: Global Open Angle Glaucoma Treatment Market Size , By Type, 2023F (%)
  • Figure 15: Global Open Angle Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 16: Global Open Angle Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 17: Global Prevalence of Glaucoma, By Type (2013,2015& 2020F, Million)
  • Figure 18: Global Closed Angle GlaucomaaTreatment Market, By Value, 2013-2017 (USD Million)
  • Figure 19: Global Closed Angle Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 20: Global Secondary Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 21: Global Secondary Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 22: Global Congenital Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 23: Global Congenital Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 24: Global Others Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 25: Global Others Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 26: Global Glaucoma Treatment Market Size, By Drug Class , 2017 (%)
  • Figure 27: Global Glaucoma Treatment Market Size, By Drug Class 2023F (%)
  • Figure 28: Global Prostaglandin Analogs Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 29: Global Prostaglandin Analogs Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 30: Global Beta Blockers Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 31: Global Beta Blockers Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 32: Global Alpha Agonist Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 33: Global Alpha Agonist Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 34: Global Carbonic Anhydrase Inhibitors Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 35: Global Carbonic Anhydrase Inhibitors Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 36: Global Others Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 37: Global Others Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 38: Global Others Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 39: Global Glaucoma Treatment Market Size, By Sales Channel, 2017 (%)
  • Figure 40: Global Glaucoma Treatment Market Size, By Sales Channel, 2017 (%)
  • Figure 41: Global Hospital Pharmacy Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 42: Global Hospital Pharmacy Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 43: Global Retail Pharmacy Glaucoma Treatment Market, By Value, 2013-2017 (USD Million)
  • Figure 44: Global Retail Pharmacy Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 45: Global Others Glaucoma Treatment , By Value, 2013-2017 (USD Million)
  • Figure 46: Global Others Glaucoma Treatment Market, By Value, Forecast, 2018-2023(USD Million)
  • Figure 47: Global Glaucoma Treatment Market Size and Share, By Region, 2017
  • Figure 48: Global Glaucoma Treatment Market Size and Share, By Region, 2023F
  • Figure 49: North America Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 50: North America Population above 65 year in Million (2015 &2030F&2050F)
  • Figure 51: North America Glaucoma Treatment Market Size, By Value, Forecast, 2018-2023(USD Million )
  • Figure 52: North America GDP, 2012-2016 (USD Trillion)
  • Figure 53: North America GDP per capita, current prices, 2013-2023F (In USD)
  • Figure 54: North America Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 55: North America Glaucoma Treatment Market: By Drug Class , By Value, 2013-2023 (USD Million)
  • Figure 56: North America Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 57: North America Glaucoma Treatment Market, Country Share, 2017 (% of Total)
  • Figure 58: North America Glaucoma Treatment , Country Share, 2023F (% of Total)
  • Figure 59: United States Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 60: United States Glaucoma Treatment Market Size, By Value, 2018E-2023F (USD Million)
  • Figure 61: Number of adults with glaucoma in the U.S. in 2017, By Age
  • Figure 62: United States Prevalence of Primary Open Angle Glaucoma (2013,2015& 2020F, Million)
  • Figure 63: USA Average Household Expenditure on Healthcare (2014-2017,USD)
  • Figure 64: Per Capita Healthcare Expenditure in United States (2012-2016, USD)
  • Figure 65: U.S. Population Ages 65 and above, 2014 and Forecast (Million)
  • Figure 66: USA health Spending by Type of Services or Products(2017)
  • Figure 67: Major U.S. Players in Glaucoma Treatment Market
  • Figure 68: United States Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 69: United States Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 70: Top 10 Largest Retail Pharmacies by Number of Stores
  • Figure 71: Leading Drug stores in the United States in 2017, based on Retail Sales (in billion U.S. dollars)
  • Figure 72: Pharmacy and drug store sales in the United States from 2012 to 2017 (in USD billion)
  • Figure 73: Canada Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 74: Canada Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 75: Canada Population 65 Years & Above (% of Total), 2012-2016
  • Figure 76: Canada Life Expectancy at birth rate (Years), 2012-2015
  • Figure 77: Prevalence of Glaucoma in Canada (2012-2016)
  • Figure 78: Canada Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 79: Canada Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 80: Canada, Growth of retail prescriptions, 2013-2017 (%)
  • Figure 81: Leading Store chains in Canada, 2016
  • Figure 82: Distribution of Pharmacies in Canada By Category
  • Figure 83: Number of pharmacies and drug stores in Canada in 2016, by employment size
  • Figure 84: Europee Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 85: Europe Glaucoma Treatment Market Size, By Value, Forecast, 2018-2023(USD Million )
  • Figure 86: Europe Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 87: North America Glaucoma Treatment Market: By Drug Class , By Value, 2013-2023 (USD Million)
  • Figure 88: Europe Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 89: Number of Pharmacies in Europe 2016
  • Figure 90: Europe Glaucoma Treatment Market, Country Share, 2017 (% of Total)
  • Figure 91: Europe Glaucoma Treatment Market, Country Share, 2023 (% of Total)
  • Figure 92: Germany Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 93: Germany Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 94: Germany Old Age Population(% of Total Population,2013-2016)
  • Figure 95: Germany Healthcare Expenditure ( USD Billion ,2014-2017)
  • Figure 96: Prevalence of Glaucoma in Germany (2012-2016 )
  • Figure 97: Germany Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 98: Germany Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 99: Germany, Market Share of Leading Organized Pharmacy Chains
  • Figure 100: Germany, Type of pharmacies
  • Figure 101: United Kingdom Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 102: United Kingdom Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 103: United Kingdom Glaucoma Prevalence (2012-2016)
  • Figure 104: United Kingdom Pharmaceutical Consumption, Daily Dosage per 1000 inhabitants per Day
  • Figure 105: U.K, Population Ages 65 and Above (% of total), 2012-2017
  • Figure 106: U.K, Health Expenditure Per Capita, PPP, 2012-2017 (USD)
  • Figure 107: Value of healthcare costs linked directly to Eye health in the United Kingdom (UK) in 2016 (in million GBP)
  • Figure 108: United Kingdom Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 109: United Kingdom Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 110: United Kingdom, Market Share of Leading Organized Pharmacy Chains
  • Figure 111: Rest of Europe Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 112: Rest of Europe Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 113: Asia Pacific Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 114: Population ages 65 and above, APAC Region, By Select Countries, 2016 (% of total)
  • Figure 115: Population ages 65 and above, APAC Region, By Select Countries, 2050 (% of total)
  • Figure 116: Asia Pacific Glaucoma Treatment Market Size, By Value, Forecast, 2018-2023(USD Million )
  • Figure 117: Asia Pacific Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 118: Asia Pacific Glaucoma Treatment Market: By Drug Class , By Value, 2013-2023 (USD Million)
  • Figure 119: Asia Pacific Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 120: Asia Pacific Glaucoma Treatment Market, Country Share, 2017 (% of Total)
  • Figure 121: Asia Pacific Glaucoma Treatment , Country Share, 2023 (% of Total)
  • Figure 122: China Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 123: China Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 124: China Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 125: China Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 126: Number of pharmacists in China, 2016
  • Figure 127: China, Market Share of Leading Organized Pharmacy Chains
  • Figure 128: Japan Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 129: Japan Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 130: Japan Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 131: Japan Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 132: Total number of Pharmacists Engaged in Medical Care in Japan from 2012 to 2016 (in 1,000s)
  • Figure 133: India Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 134: India Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 135: India Old Age population ( % of Total Population)
  • Figure 136: Diabetes Fact Sheet India 2017
  • Figure 137: India Glaucoma Treatment Market: By Indication , By Value, 2013-2023 (USD Million)
  • Figure 138: India Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 139: Rest of Asia Pacific Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 140: Rest of Asia Pacific Glaucoma Treatment Market Size By Value, Forecast, 2018-2023(USD Million)
  • Figure 141: Rest of world Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 142: Rest of World Glaucoma Treatment Market Size, By Value, Forecast, 2018-2023(USD Million )
  • Figure 143: Rest of World Glaucoma Treatment Market: By Indication , By Value, 2013-2017 (USD Million)
  • Figure 144: Rest of World Glaucoma Treatment Market: By Drug Class , By Value, 2013-2023 (USD Million)
  • Figure 145: Rest of World Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 146: Rest of world Glaucoma Treatment Market, Country Share, 2017 (% of Total)
  • Figure 147: Rest of World Glaucoma Treatment , Country Share, 2023F (% of Total)
  • Figure 148: Brazil Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 149: Brazil Glaucoma Treatment Market Size, By Value, 2018E-2023F (USD Million)
  • Figure 150: Brazil Glaucoma Treatment Market: By Indication , By Value, 2013-2017 (USD Million)
  • Figure 151: Brazil Glaucoma Treatment Market: By Sales Channel , By Value, 2013-2017 (USD Million)
  • Figure 152: Other Glaucoma Treatment Market Size, By Value, 2013-2017 (USD Million)
  • Figure 153: Other Glaucoma Treatment Market Size By Value, 2018E-2023F (USD Million)
  • Figure 154: Percentage aged 60 years and over, (2000, 2015, 2030, 2050)
  • Figure 155: Global Healthcare Expenditure, 2012-2016 (In Trillion)
  • Figure 156: Global Glaucoma Treatment Market Share Analysis, By Company Share, 2017 (%)
  • Figure 157: Sales of Alphagan/Combigan (2015-2017 , USD Million)
  • Figure 158: Sales of Lumigan/Ganfort (2015-2017 , USD Million)
  • Figure 159: Sales of Xalatan/Xalacom (2015-2017 , USD Million)
  • Figure 160: Teva Pharmaceuticals, Revenue, 2015-2017 (USD Millions)
  • Figure 161: Teva Pharmaceuticals Segmental Breakup, 2017(%)
  • Figure 162: Teva Pharmaceuticals Sales, By Region 2017 (%)
  • Figure 163: Ocular Therapeutix, Revenue, 2015-2017 (USD Thousands)
  • Figure 164: Pfizer, Revenue, 2015-2017 (USD Millions)
  • Figure 165: Pfizer Segmental Breakup, 2017(%)
  • Figure 166: Pfizer Sales, By Country, 2017 (%)
  • Figure 167: Bausch Health, Revenues, 2015-2017 (USD Million)
  • Figure 168: Bausch Health , Revenue, By Segment, 2017 (%)
  • Figure 169: Bausch Health, Revenue, By Region, 2017 (%)
  • Figure 170: Novartis, Sales, 2013-2017 (USD Millions)
  • Figure 171: Novartis Sales, By Segment 2017 (%)
  • Figure 172: Novartis Sales, By Geography,2017 (%)
  • Figure 173: Allergan Net Sales, By Geographic Location, % Share 2016
  • Figure 174: Allergan Net Revenue, By Business Segment,% Share 2017
  • Figure 175: Allergan Net Revenue, 2014-2017 (USD Billion)
  • Figure 176: Aerie Pharmaceuticals Global Pipeline
  • Figure 177: Akorn Inc. Net Revenue, By Business Segment,% Share 2017
  • Figure 178: Akorn Inc. Net Revenue, 2014-2017 (USD Million)

List of Tables

  • Table A: List of Prostaglandin Analogs Available in Market
  • Table B: List of Beta Blockers Available in Market
  • Table C: List of Alpha Agonists Available in Market
  • Table D: List of Carbonic Anhydrase Inhibitors Available in Market
  • Table E: Germany, Number of Community Pharmacies, By State 2016
目次

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Glaucoma Treatment Market. The report analyzes the global glaucoma treatment market By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others), By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others) and By Sales Channel (Hospital Pharmacy, Retail Pharmacy, Others). The report analyzes the global glaucoma treatment market By Region (North America, Europe, Asia Pacific and Rest of the World) and By Country (U.S., Canada, U.K, Germany, India, China, Japan and Brazil). The report assesses the glaucoma treatment market for the historical period of 2013-2017 and the forecast period of 2018-2023.

According to Azoth Analytics research report "Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition): Forecast to 2023 - By Indication (Open Angle, Closed Angle, Secondary, Congenital, Others), By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors)", global glaucoma treatment market is projected to display a robust growth represented by a CAGR of 4.81 % during 2018 - 2023.

The segment of Prostaglandin Analogs witnessed growth at a noteworthy rate over the past few years backed by increased prevalence of glaucoma, easy availability of dug along with rising number of hospitals and their respective pharmacies. Amongst the regions, North America accounts for the largest regional share in the global glaucoma treatment market in 2018. Key factors driving the robust growth rate of North America region include Well developed healthcare infrastructure, favorable regulatory reforms, rising prevalence of glaucoma in the region.

The report titled "Global Glaucoma Treatment Market: Analysis By Indication, By Drug Class, By Sales Channel, By Region, By Country (2018 Edition): Forecast to 2023 - By Indication (Open Angle, Closed Angle, Secondary, Congenital, Others), By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors)" has covered and analyzed the potential of Global Glaucoma Treatment Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global glaucoma treatment. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Glaucoma Treatment Market (Actual Period: 2013-2017, Forecast Period: 2018-2023

  • Global Glaucoma Treatment Market - Size, Growth, Forecast
  • By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others
  • By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others)
  • By Sales Channel - Hospital Pharmacy, Retail Pharmacy, Others

Regional Markets - North America, Europe, APAC, Rest of the World (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Glaucoma Treatment Market - Size, Growth, Forecast
  • By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others)
  • By Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonist, Carbonic Anhydrase Inhibitors, Others)
  • By Sales Channel - Hospital Pharmacy, Retail Pharmacy, Others

Country Analysis - U.S., Canada, Germany, United Kingdom, India, Japan China, Brazil (Actual Period: 2013-2017, Forecast Period: 2018-2023)

  • Glaucoma Treatment Market - Size, Growth, Forecast
  • By Indication (Open Angle Glaucoma, Closed Angle Glaucoma, Secondary Glaucoma, Congenital Glaucoma, Others)
  • By Sales Channel - Hospital Pharmacy, Retail Pharmacy, Others

Other Report Highlights

  • Market Dynamics - Drivers and Restraints
  • Market Trends
  • Porter Five Force Analysis
  • Policy and Regulatory Landscape
  • Competitive Landscape
  • Company Analysis - Allergan, Pfizer, Novartis, Aerie Pharmaceuticals, Ocular Therapeutix, Teva Pharmaceuticals.

Customization of the Report

The report could be customized according to the client's specific research requirements. No additional cost will be required to pay for limited additional research.

Table of Contents

1. Research Methodology

2. Executive Summary

3. Strategic Recommendations

4. Glaucoma Treatment Market Overview

5. Global Glaucoma Treatment: Growth and Forecast

  • 5.1 By Value (2013-2017)
  • 5.2 By Value (2018-2023)

6. Global Glaucoma Treatment Market: Analysis By Indication

  • 6.1 Global Glaucoma Treatment Market-By Indication: Breakdown(%)
    • 6.1.1 Global Glaucoma Treatment Market Size and Share, By Indication, 2017
    • 6.1.2 Global Glaucoma Treatment Market Size and Share, By Indication, 2023
  • 6.2 Global Open Angle Glaucoma Treatment Market Overview
    • 6.2.1 By Value (2013-2023)
  • 6.3 Global Closed Angle Glaucoma Treatment Market Overview
    • 6.3.1 By Value (2013-2023)
  • 6.4 Global Secondary Glaucoma Treatment Market Overview
    • 6.4.1 By Value (2013-2023)
  • 6.5 Global Congenital Glaucoma Treatment Market Overview
    • 6.5.1 By Value (2013-2023)
  • 6.6 Global Others Glaucoma Treatment Market Overview
    • 6.6.1 By Value (2013-2023)

7. Global Glaucoma Treatment Market: Analysis By Drug Class

  • 7.1 Global Glaucoma Treatment Market: By Drug Class: Breakdown(%)
    • 7.1.1 Global Glaucoma Treatment Market Size and Share, Market-By Drug Class, 2017
    • 7.1.2 Global Glaucoma Treatment Market Size and Share, Market-By Drug Class ,2023
  • 7.2 Global Prostaglandin Analogs Glaucoma Treatment Market Overview
    • 7.2.1 By Value (2013-2023)
    • 7.2 Global Beta Blockers Glaucoma Treatment Market Overview
    • 7.2.1 By Value (2013-2023)
  • 7.3 Global Alpha Agonist Glaucoma Treatment Market Overview
    • 7.3.1 By Value (2013-2023)
  • 7.4 Global Carbonic Anhydrase Inhibitors Glaucoma Treatment Market Overview
    • 7.4.1 By Value (2013-2023)
  • 7.5 Global Others Glaucoma Treatment Market Overview
    • 7.5.1 By Value (2013-2023)

8. Global Glaucoma Treatment: Sales Channel Analysis

  • 8.1 Global Glaucoma Treatment Market-By Sales Channel : Breakdown(%)
    • 8.1.1 Global Glaucoma Treatment Market Size and Share, By Sales Channel, 2017
    • 8.1.2 Global Glaucoma Treatment Market Size and Share, By Sales Channel, 2023
  • 8.2 Global Hospital Pharmacy Glaucoma Treatment Market Overview
    • 8.2.1 By Value (2013-2023)
  • 8.3 Global Retail Pharmacy Glaucoma Treatment Market Overview
    • 8.3.1 By Value (2013-2023)
  • 8.4 Global Others Glaucoma Treatment Market Overview
    • 8.4.1 By Value (2013-2023)

9. Global Glaucoma Treatment Market: Regional Analysis

  • 9.1 Global Glaucoma Treatment Market, By Region: Breakdown (%)
    • 9.1.1 Global Glaucoma Treatment Market Size, By Region, 2017 (%)
    • 9.1.2 Global Glaucoma Treatment Market Size, By Region, 2023 (%)
  • 9.2 North America Glaucoma Treatment Market: An Analysis
    • 9.2.1 By Value (2013-2017)
    • 9.2.2 By Value (2018-2023)
  • 9.3 North America Glaucoma Treatment Market: Segment Analysis
    • 9.3.1 North America Glaucoma Treatment Market: By Indication , By Value(2013-2023)
    • 9.3.2 North America Glaucoma Treatment Market: By Drug Class , By value (2013-2023)
    • 9.3.4 North America Glaucoma TreatmentMarket: By Sales Channel, By Value (2013-2023)
  • 9.4 North America Glaucoma Treatment Market: Country Analysis (U.S. and Canada)
    • 9.4.1 U.S. Glaucoma Treatment Market, By Value (2013-2023)
    • 9.4.1.1 U.S. Glaucoma Treatment Market, By Indication, By Value (2013-2023
    • 9.4.1.2 U.S. Glaucoma Treatment, By Sales Channel, By Value (2013-2023)
    • 9.4.2 Canada Glaucoma Treatment Market, By Value (2013-2023)
    • 9.4.2.1 Canada Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.4.2.2 Canada Glaucoma TreatmentMarket, By Sales Channel By Value (2013-2023)
  • 9.5 Europe Glaucoma Treatment Market: An Analysis
    • 9.5.1 By Value (2013-2017)
    • 9.5.2 By Value (2018-2023)
  • 9.6 Europe Glaucoma Treatment Market: Segment Analysis
    • 9.6.1 Europe Glaucoma Treatment Market: By Indication
    • 9.6.2 Europe Glaucoma Treatment Market: By Drug Class
    • 9.6.3 Europe Glaucoma TreatmentMarket: By Sales channel
  • 9.7 Europe Glaucoma Treatment Market: Country Analysis (Germany, U.K., Rest of Europe)
    • 9.7.1 Germany Glaucoma Treatment Market, By Value (2013-2023)
    • 9.7.1.1 Germany Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.7.1.2 Germany Glaucoma Treatment Market, By Sales Channel, By Value (2013-2023)
    • 9.7.2 United Kingdom Glaucoma Treatment Market, By Value (2013-2023)
    • 9.7.2.1 United Kingdom Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.7.2.2 United Kingdom Glaucoma Treatment Market, By Sales Channel; , By Value(2013-2023)
    • 9.7.4 Rest of Europe Glaucoma Treatment Market, By Value (2013-2023)
  • 9.8 Asia Pacific Glaucoma Treatment Market: An Analysis
    • 9.8.1 By Value (2013-2017)
    • 9.8.2 By Value (2018-2023)
  • 9.9 Asia Pacific Glaucoma Treatment Market: Segment Analysis
    • 9.9.1 Asia Pacific Glaucoma Treatment Market: By Indication
    • 9.9.2 Asia Pacific Glaucoma Treatment Market: By Drug Class
    • 9.9.3 Asia Pacific Glaucoma TreatmentMarket: By Sales Channel
  • 9.10 Asia Pacific Glaucoma Treatment Market: Country Analysis (India, China Japan & Rest of Asia Pacific)
    • 9.10.1 China Glaucoma Treatment Market, By Value (2013-2023)
    • 9.10.1.1 China Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.10.1.2 China Glaucoma Treatment Market, By Sales Channel, By Value (2013-2023)
    • 9.10.2 Japan Glaucoma Treatmentes Market, By Value (2013-2023)
    • 9.10.2.1 Japan Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.10.2.3 Japan Glaucoma TreatmentMarket, By Sales Channel, By value(2013-2023)
    • 9.10.3 India Glaucoma Treatment Market, By Value (2013-2023)
    • 9.10.3.1 India Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.10.3.2 India Glaucoma Treatment Market, By Sales Channel, By Value (2013-2023)
    • 9.10.4 Rest of Asia Pacific Glaucoma Treatment Market, By Value (2013-2023)
  • 9.11 Rest of World Glaucoma Treatment Market: An Analysis
    • 9.11.1 By Value (2013-2017)
    • 9.11.2 By Value (2018-2023)
  • 9.12 Rest of World Glaucoma Treatment Market: Segment Analysis
    • 9.12.1 Rest of World Glaucoma Treatment Market: By Indication, By Value(2013-2023)
    • 9.12.2 Rest of World Dental System and Parts Market: By Drug Class n, By Value(2013-2023)
    • 9.12.3 Rest of World Glaucoma Treatment Market: By Sales Channel, By Value(2013-2023)
  • 9.13 Rest of World Glaucoma Treatment Market: Country Analysis (Brazil & Others)
    • 9.13.1 Brazil Glaucoma Treatment Market, By Value (2013-2023)
    • 9.13.1.1 Brazil Glaucoma Treatment Market, By Indication, By Value (2013-2023)
    • 9.13.1.2 Brazil Glaucoma Treatment Market: By Sales Channel, By Value(2013-2023)
    • 9.13.3 Others Glaucoma Treatment Market, By Value (2013-2023)

10. Market Dynamics

  • 10.1 Drivers
  • 10.2 Challenges

11. Market Trends

12. Competitive Landscape

13. Policy and Regulatory Landscape

14. Porter's Five Forces Analysis

15. SWOT Analysis

16. Company Profiles

  • 16.1 Teva Pharmaceuticals
  • 16.2 Ocular Therapeutix
  • 16.3 Pfizer
  • 16.4 Bausch Health
  • 16.5 Novartis
  • 16.6 Allergan Plc.
  • 16.7 Aerie Pharmaceuticals
  • 16.8 Akorn Inc.
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.